Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
News|Articles|August 1, 2024
Psychiatry Month in Review: July 2024
Author(s)Chelsie Derman
This month in review captures the top news in the psychiatry field during July.
Advertisement
Advertisement
This Month in Review for July encompasses the top US Food and Drug Administration (FDA) news, pipeline updates, and discovered associations in the psychiatry field. The recap also captures insights from psychiatry experts on topics ranging from schizophrenia to PTSD. On the latter subject, the Month in Review includes commentary from a psychiatry expert on the potential game-changer MDMA-assisted therapy, with an FDA decision now less than a month away in August.
Related to this article
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Once-monthly efimosfermin alfa reduced liver stiffness, ELF, and PRO-C3 through 52 weeks in MASH with F2–F4 fibrosis, including compensated cirrhosis.
Alvar Agustí, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.
In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
Advertisement
Advertisement